Mirum Pharmaceuticals, Inc. (MIRM)
| Market Cap | 6.53B +226.5% |
| Revenue (ttm) | 569.61M +50.2% |
| Net Income | -798.84M |
| EPS | -15.17 |
| Shares Out | 60.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,765,434 |
| Open | 103.93 |
| Previous Close | 102.93 |
| Day's Range | 103.76 - 109.60 |
| 52-Week Range | 40.00 - 112.00 |
| Beta | 0.52 |
| Analysts | Strong Buy |
| Price Target | 127.93 (+19.38%) |
| Earnings Date | May 6, 2026 |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap... [Read more]
Financial Performance
In 2025, Mirum Pharmaceuticals's revenue was $521.31 million, an increase of 54.74% compared to the previous year's $336.89 million. Losses were -$23.36 million, -73.43% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price target is $127.93, which is an increase of 19.38% from the latest price.
News
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
Raymond James analyst Ryan Deschner raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $165 from $164 and keeps a Strong Buy rating on the shares. Published first on
Mirum Pharmaceuticals price target raised to $145 from $125 at TD Cowen
TD Cowen raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $145 from $125 and keeps a Buy rating on the shares. The firm updated its model following its
Mirum Pharmaceuticals price target raised to $142 from $128 at RBC Capital
RBC Capital analyst Joe Kim raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $142 from $128 and keeps an Outperform rating on the shares. The company’s Q1 earnings
Mirum Pharmaceuticals price target raised to $129 from $112 at Baird
Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $129 from $112 and keeps an Outperform rating on the shares. The firm updated its model following beat and
Mirum Pharmaceuticals price target raised to $136 from $130 at Stifel
Stifel raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $136 from $130 and keeps a Buy rating on the shares.
Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
Evercore ISI raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $138 from $135 and keeps an Outperform rating on the shares.
Mirum Pharmaceuticals price target raised to $185 from $175 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $185 from $175 and keeps a Buy rating on the shares post the Q1 report. The company disclosed
Mirum Pharmaceuticals reports Q1 EPS ($13.43), consensus (35c)
Reports Q1 revenue $159.9M, consensus $148.2M. “2026 is off to an excellent start, driven by strong commercial momentum, the recent VISTAS and AZURE-1 topline results, disciplined clinical execution, ...
Mirum Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 net product sales rose to $160M, driven by strong LIVMARLI uptake in PFIC and international markets. Full-year guidance increased to $660–$680M, with pipeline expansion into PSC, hepatitis delta, and FOP. Bluejay acquisition and Incyte licensing support future growth.
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update.
Mirum Pharmaceuticals price target raised to $140 from $130 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $140 from $130 and keeps an Overweight rating on the shares. The firm cites the announcement that the
Mirum's rare liver disease drug meets main goal in mid-stage study
Mirum Pharmaceuticals said on Monday its experimental drug, volixibat, met the main goal of a mid-stage study by reducing severe itching or pruritus in patients with a type of rare liver disease.
Mirum Pharmaceuticals price target raised to $175 from $150 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $175 from $150 and keeps a Buy rating on the shares after the company reported positive topline data
Mirum announces primary endpoint met in VISTAS Phase 2b study of volixibat
Mirum Pharmaceuticals (MIRM) announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral ileal bile acid transporter, IBAT, inhibitor, in patients...
Mirum Pharmaceuticals Transcript: Study result
Volixibat achieved significant and clinically meaningful reduction in pruritus for PSC patients in the VISTAS phase II-B study, with a strong safety profile and robust efficacy across pruritus severities. AZURE-1 phase II-B brelovitug data in hepatitis delta also met primary endpoints, supporting upcoming regulatory filings.
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis.
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with PSC on May 4, 2026.
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026.
Mirum Pharmaceuticals price target raised to $130 from $125 at Stifel
Stifel raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $125 and keeps a Buy rating on the shares.
Mirum Pharmaceuticals price target raised to $112 from $95 at Baird
Baird analyst Brian Skorney raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $112 from $95 and keeps an Outperform rating on the shares. The firm updated its model
Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $150 from $130 and keeps a Buy rating on the shares after the company reported the interim analysis
Mirum announces primary endpoint met in Phase 2b portion of AZURE-1 study
Mirum Pharmaceuticals (MIRM) announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an investigational monoclonal antibody designed to bind hepatiti...
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Egetis Appoints Tiago Nunes as Chief Medical Officer
STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Office...